Inhibidores de la integrasa y raltegravir en el manejo de la infección por vírus de la inmunodeficiencia humana en la era de la resistencia a múltiples medicamentos: [revisión]

Guevara, Fredy; Blanco, Francisco; Arredondo, Miguel.
Infectio ; 14(2): 132-142, jun. 2010.
Artigo em Espanhol | LILACS | ID: lil-560942

Documentos relacionados

  1. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study.
  2. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
  3. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
  5. Retroviral integrase: Structure, mechanism, and inhibition.
  6. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review.
  7. A potential drug interaction between phenobarbital and dolutegravir: A case report.
  8. HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment.
  9. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
  10. Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen.